Metsera Inc.(MTSR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MTSR Metsera Inc.

Post-Market Trading 03-31 18:53:56 EDT

27.22

-0.78

-2.79%

盘后27.22

+0.000.00%

16:36 EDT

High27.71	Low26.15	Vol534.29K
Open27.26	D1 Closing28.00	Amplitude5.59%
Mkt Cap2.86B	Tradable Cap467.84M	Total Shares105.05M
T/O14.57M	T/O Rate3.11%	Tradable Shares17.19M
P/B-11.28	ROE-108.40%	EPS-14.49
52wk High32.81	52wk Low23.08	P/E-1.88
Dividend0.00	Div.Yield0.00	ROA-27.09%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MTSR","market":"US","secType":"STK","nameCN":"Metsera Inc.","latestPrice":27.22,"timestamp":1743451200000,"preClose":28,"halted":0,"volume":534290,"hourTrading":{"tag":"盘后","latestPrice":27.22,"preClose":27.22,"latestTime":"16:36 EDT","volume":9442,"amount":257011.24,"timestamp":1743453379112},"delay":0,"floatShares":17187500,"shares":105050219,"eps":-14.490661,"marketStatus":"Post-Market Trading","change":-0.78,"latestTime":"03-31 18:53:54 EDT","open":27.26,"high":27.71,"low":26.145,"amount":14570424.9027,"amplitude":0.055893,"askPrice":31.47,"askSize":100,"bidPrice":26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.490661,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743465600000},"marketStatusCode":4,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":28,"preHourTrading":{"tag":"盘前","latestPrice":27,"preClose":28,"latestTime":"08:25 EDT","volume":420,"amount":11187.9201,"timestamp":1743423958655},"postHourTrading":{"tag":"盘后","latestPrice":27.22,"preClose":27.22,"latestTime":"16:36 EDT","volume":9442,"amount":257011.24,"timestamp":1743453379112},"volumeRatio":1.028246},"requestUrl":"/m/hq/s/MTSR/wiki","defaultTab":"wiki","newsList":[{"id":"2522795538","title":"BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522795538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522795538?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:44","pubTimestamp":1742989499,"startTime":"0","endTime":"0","summary":"BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio ProgressMarch 26 (Reuters) - Metsera Inc MTSR.O:METSERA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA92XKL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2522187964","title":"Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187964","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187964?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:24","pubTimestamp":1742988265,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2522935879","title":"Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935879?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:23","pubTimestamp":1742988224,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","MTSR"],"gpt_icon":0},{"id":"2522820423","title":"Metsera Inc: Completed IPO With Gross Proceeds of Approximately $316.2 Mln, Extending Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2522820423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522820423?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986837,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA92XKL3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2522829878","title":"Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522829878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522829878?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025. Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1. Oral formulation optimization study on track to support initiation of clinical trials for MET-224 and MET097 , with MET-224 data expected in late 2025. Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027. NEW YORK, March 26, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial results and provided an update on pipeline progress.With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be anot","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4097","MTSR","BK4139","RA","PRGS","IPO"],"gpt_icon":0},{"id":"2518783956","title":"Metsera, Inc. Approves 2024 Executive Cash Bonuses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783956","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518783956?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:33","pubTimestamp":1741638825,"startTime":"0","endTime":"0","summary":"Metsera, Inc. ( ($MTSR) ) just unveiled an update. On March 7, 2025, Metsera, Inc. announced that its Board of Directors approved the 2024 annual c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metsera-inc-approves-2024-executive-cash-bonuses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metsera-inc-approves-2024-executive-cash-bonuses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2516530651","title":"Q4 2024 Amneal Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2516530651","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516530651?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 18:02","pubTimestamp":1740823351,"startTime":"0","endTime":"0","summary":"Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc.Anastasios Konidaris; Chief Financial Officer, Executive Vice President; Amneal Pharmaceuticals Inc.Joe Renda; Senior Vice President, Chief Commercial Officer-Specialty; Amneal Pharmaceuticals Inc.Jason Daly; Senior Vice President, Chief Legal Officer, Corporate Secretary; Amneal Pharmaceuticals Inc.Thank you, Tony. Good morning, everyone. At Amneal, we're much more than another generics company. We are an American biopharmaceutical company with a track record of excellence in delivering high-quality complex pharmaceuticals at speed and scale. We are a leader in an essential industry, providing millions of patients with access to affordable and innovative medicines. 2024 was an exceptional year where Amneal delivered stellar financial performance with double-digit revenue and adjusted EBITDA growth and reducing net leverage below 4 times. All segments grew revenues double digits. This ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-amneal-pharmaceuticals-inc-100231626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTSR"],"gpt_icon":0},{"id":"2514902839","title":"Metsera to Present at TD Cowen’s 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514902839","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514902839?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 26, 2025  -- Metsera, Inc.  , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metsera-present-td-cowen-45th-120000026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4566","BK4207","BK4127","TD","MTSR","BK4585","COWN"],"gpt_icon":0},{"id":"2514043635","title":"Wall Street bullish on Metsera following January IPO on obesity drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2514043635","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514043635?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 03:04","pubTimestamp":1740510255,"startTime":"0","endTime":"0","summary":"Investing.com --Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a potential acquisition target for larger biopharma firms looking to enter the obesity market.Guggenheim rated Metsera a \"Buy\" with a $56 price target on its ultra-long-acting nutrient-stimulating hormone  analog pipeline. The firm sees Metsera’s lead GLP-1 receptor agonist, MET-097i, as a strong contender in the obesity market, with combination potential driving further value. Guggenheim noted that positive data in late 2025 could double the stock’s value over the next 18-24 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-bullish-metsera-following-190415270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MTSR"],"gpt_icon":0},{"id":"2514010770","title":"Why this newly public biotech could become a force in obesity treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2514010770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514010770?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 02:42","pubTimestamp":1740508920,"startTime":"0","endTime":"0","summary":"Metsera's GLP-1 peptide has a long half-life, meaning it could be administered once a month. And the company is ready to scale up.There's a new kid on the block when it comes to drug companies developing treatments for obesity, and this one has a clear advantage over rivals.Metsera Inc. , a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing treatments, as well as an oral peptide delivery technology, according to Evercore ISI analysts.That's not all. Metsera's GLP-1 peptide also has a long half-life, which could allow for monthly dosing, a more convenient administration system than the current approved drugs, which require weekly injections.\"Between the long half-life of GLP-1 peptide and slightly improved bioavailability in oral tech, Metsera's API math for oral is quite reasonable/doable,\" the analysts wrote.The company has launched a 28-week, double-blind, pla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK6520","BK4599","BK4007","MTSR","BK4588","OTX.SI","BK4139","BK4585","BK6100","AMRX"],"gpt_icon":0},{"id":"2514006090","title":"BofA Securities Initiates Metsera at Buy With $38 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514006090","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514006090?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 22:49","pubTimestamp":1740494941,"startTime":"0","endTime":"0","summary":"Price: 30.26, Change: +0.45, Percent Change: +1.51","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2514097110","title":"BUZZ-U.S. STOCKS ON THE MOVE-  Eli Lilly, Krispy Kreme, PayPal","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097110","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514097110?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 22:30","pubTimestamp":1740493805,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE- Eli Lilly, Krispy Kreme, PayPalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL6N3PG0G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IART","NVIW.SI","BBNX","AU","HRMY","SRE","AS","NVDS.UK","3NVD.UK","CIVI","DOMH","HD","PTLO","CLF","ZM","BKSY","NTRA","EVER","NVD2.UK","YY","NIO.SI","ONVO","PYPL","NVD3.UK","CAKE","SNVD.UK","KDP","CSCO","EVS.SI","NEM","CHGG","MTSR","02020","LLY","DNUT","PLNT"],"gpt_icon":1},{"id":"2514099996","title":"Metsera Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099996?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:05","pubTimestamp":1740488700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTSR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 08:05 ET (13:05 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR"],"gpt_icon":0},{"id":"2514962060","title":"Evercore ISI Initiates Metsera at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514962060","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514962060?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:00","pubTimestamp":1740488448,"startTime":"0","endTime":"0","summary":"Evercore ISI Initiates Metsera at Outperform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2514096755","title":"Metsera Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096755","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096755?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:50","pubTimestamp":1740487800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTSR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:50 ET (12:50 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2514355093","title":"BUZZ-U.S. STOCKS ON THE MOVE- Zoom Communications, Home Depot, Civitas Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355093","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355093?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:10","pubTimestamp":1740485423,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zoom Communications, Home Depot, Civitas ResourcesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL6N3PG0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09866","NVIW.SI","NVDY","09888","RIOT","NVDU","MARA","EVER","LU1069344957.HKD","NVDA","NVDL","NVDS","02015","3NVD.UK","SNVD.UK","ZM","LU0957808578.USD","EVS.SI","U","XPEV","MTSR","LI","COIN","02020","LU0043850808.USD","HIMS","BK4587","LU1548497426.USD","DOMH","LU0056508442.USD","NVD2.UK","89888","NIO.SI","82020","IE0004091025.USD","NVDS.UK","CIVI","NVDX","BIDU","09868","HD","NVD","NIO","2NVD.UK","YY","ANPDY","NVD3.UK","AS","LU2092627202.USD","NVDD"],"gpt_icon":1},{"id":"2514060775","title":"BUZZ-BofA starts coverage on weight-loss drug developer Metsera with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514060775","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514060775?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 19:49","pubTimestamp":1740484167,"startTime":"0","endTime":"0","summary":"BUZZ-BofA starts coverage on weight-loss drug developer Metsera with 'buy' rating** BofA Global Research starts coverage on weight-loss drug developer Metsera MTSR.O with \"buy\" rating and $38 PT** PT represents a 27.5% upside to stock's last close** MTSR is poised to \"break into the obesity market\", which is projected to reach ~$170 bln by 2030, with a unique combination of both \"oral and injectable platforms\", setting it apart from its peers - brokerage** Company's lead obesity assets, MET-097i and MET-233i, have \"comparatively long half-lives\" and offer a convenient dosing schedule, with no dose changes needed at first, and just monthly injections afterwards, BofA says** MTSR's oral peptide, MET-224o, could have \"bioavailability that is 5-6x higher\" than the currently approved oral peptide, Novo Nordisk's NOVOb.CO Rybelsus - brokerage** Estimates risk-adjusted revenue of $2.1 bln and $2.5 bln by 2040 for MTSR's lead assets MET-097 and MET-097+MET-233, respectively  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAC","MTSR"],"gpt_icon":0},{"id":"2514060974","title":"Metsera initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2514060974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514060974?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 19:40","pubTimestamp":1740483610,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 programs in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metsera-initiated-with-an-outperform-at-evercore-isi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metsera-initiated-with-an-outperform-at-evercore-isi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTSR"],"gpt_icon":0},{"id":"2514677150","title":"Guggenheim Initiates Metsera at Buy With $56 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514677150","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514677150?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 19:32","pubTimestamp":1740483151,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Metsera at Buy With $56 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2514632067","title":"Cantor Fitzgerald Initiates Metsera at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2514632067","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514632067?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 19:23","pubTimestamp":1740482634,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Metsera at Overweight","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metsera.com","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":0.029},{"period":"3month","weight":0.5556},{"period":"ytd","weight":0.5556}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Metsera Inc.","nameEN":"Metsera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Metsera Inc.(MTSR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Metsera Inc.(MTSR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Metsera Inc.,MTSR,Metsera Inc.股票,Metsera Inc.股票老虎,Metsera Inc.股票老虎国际,Metsera Inc.行情,Metsera Inc.股票行情,Metsera Inc.股价,Metsera Inc.股市,Metsera Inc.股票价格,Metsera Inc.股票交易,Metsera Inc.股票购买,Metsera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Metsera Inc.(MTSR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Metsera Inc.(MTSR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction